MedTrace Logo

24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost

NCT00444184 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2014-05-12

No results posted yet for this study

Summary

This 8-week, crossover study will compare the quality of 24-hour IOP control with TTFC versus travoprost when both medications are dosed in the evening. Such a crossover comparison may determine the real efficacy of the new fixed combination versus travoprost monotherapy. The results should enhance the investigators understanding on the best dosing of TTFC and may influence its clinical use in Europe. Finally, the results would better delineate the future role of TTFC in glaucoma management after PG monotherapy, or instead of unfixed therapy with PG analogs and timolol. This study should assist the general ophthalmologist worldwide to plan optimal stepwise medical therapy.

Conditions

Interventions

DRUG

Travoprost/timolol fixed combination, travoprost

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Anastasios GP Konstas, MD, PhD · Associate Professor and Head of the Glaucoma Unit, 1st University Department of Ophthalmology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
29 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00444184 on ClinicalTrials.gov